alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 126–150 of 326 studies in JAMA Neurology (page 6 of 14) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of these 326 studies, in this order: BibTeX (.bib) · RIS (.ris)

This list as a page: JAMA Neurology in the library →

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 67 out of 100. JAMA neurology 2023-12-01

Data from 3960 MRI sessions among 1141 participants were included: 252 pathogenic variant carriers from DIAN (mean [SD] age, 38.4 [11.2] years; 137 [54%] female), 571 older adults from ADNI (mean [SD] age, 72.8 [7.3] years; 274 [48%] female), and 318 older adults from HABS (mean [SD] age, 72.4 [7.6] years; 194 [61%] female). 3 key findings →

Design: cohort study Participants: 1,141 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association Between Blood Pressure and Later-Life Cognition Among Black and White Individuals

✓ Peer-reviewed alzhub usefulness score 67 out of 100. JAMA neurology 2020-07-01

Among 34 349 participants, 19 378 individuals who were free of stroke and dementia and had longitudinal BP, cognitive, and covariate data were included in the analysis. 2 key findings →

Design: longitudinal study Participants: 349 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community

✓ Peer-reviewed alzhub usefulness score 67 out of 100. JAMA neurology 2016-01-01

In persons selected from a population-based study, elevated amyloid levels at baseline were associated with worse cognition and imaging biomarkers at baseline and with greater clinical decline and neurodegeneration. 5 key findings →

Design: longitudinal study Participants: 286 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging

✓ Peer-reviewed alzhub usefulness score 67 out of 100. JAMA neurology 2019-11-01

Blood biomarkers able to diagnose Alzheimer disease (AD) at the preclinical stage would enable trial enrollment when the disease is potentially reversible. 4 key findings →

Design: case-control study Participants: 161 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2023-05-01

Of 386 participants, 199 (52%) were female, and the mean (SD) age was 68 (8) years. 3 key findings →

Design: cohort study Participants: 113 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2019-05-01

Early tau deposition was elevated in women compared with men in individuals on the Alzheimer disease trajectory. 5 key findings →

Design: cross-sectional Participants: 89 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2014-10-01

The agreement between Aβ classification with CSF Aβ42 and 18F-flutemetamol positron emission tomography was very high (κ = 0.85). 3 key findings →

Design: cross-sectional Participants: 118 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2015-09-01

Within-person changes in CSF biomarkers were also compared with changes in cortical PiB binding and progression to a CDR higher than 0 at follow-up. 2 key findings →

Design: cohort study Participants: 169 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2020-10-01

However, the clinical presentation, associated factors, frequency in community-based cohorts, genetic characteristics, and cognitive trajectories associated with the quadruple misfolded proteins phenotype are not well understood. 5 key findings →

Design: cohort study Participants: 375 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2015-04-01

At 48 months, group differences between clinical progressors and non-progressors were significant for self (2.13, SE=0.45, P Conclusions and relevance Demonstrating long-term clinical benefit will be critical for the success of recently launched secondary prevention trials. 1 key finding →

Design: longitudinal study Participants: 468 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2019-10-01

Statistically significant effects of AZD0530 treatment were not found on relative CMRgl reduction in an Alzheimer disease-associated region of interest or on secondary clinical or biomarker measures. 3 key findings →

Participants: 159 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2022-10-01

Among 580 participants (PREVENT-AD, 128; HABS, 153; AIBL, 48; Knight ADRC, 251), mean (SD) age ranged from 67 (5) to 76 (6) years across cohorts, with between 55% (137/251) and 74% (95/128) female participants. 2 key findings →

Design: cohort study Participants: 580 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2018-04-01

However, the extent to which increasing age, Aβ, and ε4 are associated with memory decline remains unclear, and the age at which memory decline begins for Aβ-positive ε4 carriers and noncarriers has not been determined. 5 key findings →

Design: longitudinal study Participants: 1,583 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2016-10-01

GBA mutations (β = 4.65; 95% CI, 1.72-7.58; P = .002), E326K (β = 3.42; 95% CI, 0.66-6.17; P = .02), and GBA variants combined as a single group (β = 4.01; 95% CI, 1.95-6.07; P = 1.5 × 10-4) were associated with a more rapid decline in MDS-UPDRS III score. 4 key findings →

Design: longitudinal study Participants: 740 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2022-01-01

Alzheimer disease comorbid pathologic characteristics are common and are associated with more rapid cognitive decline in patients with dementia with Lewy bodies (DLB); therefore, it is anticipated that plasma p-tau concentrations may have utility in assessing cognitive impairment in individuals with this disorder. 4 key findings →

Design: cohort study Participants: 371 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of Vascular Risk Factors and Genetic Factors With Penetrance of Variants Causing Monogenic Stroke

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2022-12-01

It is uncertain whether typical variants causing monogenic stroke are associated with cerebrovascular disease in the general population and why the phenotype of these variants varies so widely. 4 key findings →

Design: cohort study Participants: 454 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2023-06-01

Longitudinal tau positron emission tomography (PET) is a relevant outcome in clinical trials evaluating disease-modifying therapies in Alzheimer disease (AD). 4 key findings →

Design: cohort study Participants: 215 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2021-04-01

Patients with preserved cognition and mild-verbal memory/semantic fluency were younger (mean [SD] age, 36.5 [9.8] years and 38.2 [11.1] years) and had shorter disease duration (mean [SD] 8.0 [7.3] years and 8.3 [7.6] years) compared with patients with mild-multidomain (mean [SD] age, 42.6 [11.2] years; mean [SD] disease duration, 12.8 [9.6] years; P < .001), severe-executive/attention (mean [SD] age, 42.9 [11.7] years; mean [SD] disease duration, 12.2 [9.5] years; P < .001), and severe-multidomain (mean [SD] age, 44.0 [11.0] years; mean [SD] disease duration, 13.3 [10.2] years; P < .001) phenotypes. 3 key findings →

Design: cross-sectional Participants: 235 Evidence: moderate

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed